ClinicalTrials.gg
Active, not recruitingNCT05506943Updated Nov 10, 2026

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

A Phase 2/3 interventional study of CTX-009 and Paclitaxel in Biliary Tract Cancer, Cholangiocarcinoma and Gall Bladder Cancer, sponsored by Compass Therapeutics. Active, not recruiting at 34 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Primary conditionGallbladder NeoplasmsRegistry: Biliary Tract NeoplasmsReclassifiedWhy we changed it
Registry
Biliary Tract Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Gallbladder Neoplasms
Why
  1. The study's listed conditions name Gallbladder Neoplasms, a narrower term within Biliary Tract Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Compass Therapeutics · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 10, 2026Primary outcomes revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 147 studies in Gallbladder Neoplasms with a site in United States — 16 open to participants now, 27 under way, 6 of them phase 3. Gallbladder Neoplasms · United States.

Enrollment
20th of 127
168 · median 44
Started
2023
with 3 others
Phase 2/3
4 of 147
none open now
Primary completion
2027-08
later than 12 of 26 live
Registered
131st of 147
by date

Among the 147 studies in Gallbladder Neoplasms with a site in United States, this one is the 20th largest by enrollment of the 127 interventional ones that give a count, is one of 4 that started in 2023, is one of 4 in phase 2/3, reaches primary completion later than 12 of the 26 other live ones, and was the 131st registered.

Gallbladder Neoplasms

301 studies on the registry are indexed under Gallbladder Neoplasms; 65 are open to participants now.

Browse Gallbladder Neoplasms studies →

Open to participants now

16 of the 147 studies in Gallbladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Gallbladder Neoplasms studies recruiting now, 24 (56%) set no upper age limit and 8 (19%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Gallbladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.

03

Conditions studied

  • Biliary Tract Cancer
  • Cholangiocarcinoma
  • Gall Bladder Cancer
  • Ampullary Cancer

Browse trials for

04

In context

Gallbladder Neoplasms Reclassified

301 studies on the registry are indexed under Gallbladder Neoplasms; 65 are open to participants now.

This study's enrollment of 168 is above the median of 56 across 222 interventional studies indexed under Gallbladder Neoplasms.

Browse Gallbladder Neoplasms studies →

Lead sponsor

Compass Therapeutics is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Compared within Gallbladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Biliary Tract Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. or cytologically confirmed unresectable advanced, , or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma)
  3. Patients must have radiologically documented progression after a prior gemcitabine and platinum containing chemotherapy regimen as therapy for locally advanced unresectable or metastatic disease.

    1. Patients who received perioperative treatment (adjuvant and ) may be eligible, as determined by the Sponsor Medical Monitor.
    2. Patients whose first line regimen was modified due to toxicity before disease progression, may be eligible, as determined by the Sponsor Medical Monitor.
  4. At least one lesion measurable as defined by v1.1
  5. (ECOG) Performance Status 0-1
  6. Predicted of at least 12 weeks
  7. No evidence of ongoing infection and adequate biliary excretion or patients whose adequate biliary excretion can be confirmed with the following procedures:

    1. Patients who underwent endoscopic retrograde biliary drainage (ERBD) at least 1 week before the drug treatment
    2. Patients with endobiliary stents are eligible, provided there is no evidence of obstruction
    3. Patients free of any signs of active or suspected uncontrolled infection after a drainage procedure
    4. Patients free of any risk of hemorrhage and with incision completely healed
  8. Adequate bone marrow, hepatic, and renal function within 14 days of randomization as described below. (Patient must be free of G-CSF treatment and blood transfusion within 14 days prior to the lab test):

    1. (ANC) ≥ 1,500/mm3
    2. ≥ 9.0 g/dL
    3. count ≥ 100,000/mm3
    4. Total ≤ 1.5 X
    5. /ALT ≤ 3.0 X ULN (≤5 X ULN in case of hepatic metastasis)
    6. Estimated ≥ 30 mL/min based on Cockcroft-Gault
    7. Urine protein ≤ 1+ by Dipstick (Only when urinalysis shows a protein dipstick result of > 1 positive (+), the total protein volume (\<1.0 g/24hr) can be confirmed with a 24-hour urine test.)
    8. Serum amylase and lipase level ≤ 3X ULN
    9. Serum Albumin ≥ 3.0 g/dL
  9. Female patients who are women of (WCBP) must have a negative pregnancy test (serum-hCG or urine-hCG performed at the Investigator's discretion) within 14 days of randomization
  10. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years or commit to use 2 acceptable forms of (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, or any form of hormonal contraceptives) or abstinence for the duration of the study and for 6 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 6 months following the last dose of study treatment.
  11. Signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Form (ICF) before any protocol-directed screening procedures are performed

Exclusion criteria

EXCLUSION CRITERIA

  1. Patients who are eligible to be treated with a molecularly targeted therapy on a labelled regimen after receiving chemotherapy. Patients who received a molecularly targeted therapy as part of their first line treatment may be eligible, as determined by the Sponsor Medical Monitor.
  2. From the time point of screening,

    1. Less than 4 weeks have elapsed since patients had a surgery or major procedure
    2. Less than 2 weeks have elapsed from the last treatment date since patients had any radiation therapy
  3. Patients with percutaneous transhepatic biliary drains (PTBD)
  4. Prior to the initial treatment of study drug,

    1. Less than 2 weeks have elapsed since patients had chemotherapy or hormone therapy
    2. Less than 2 weeks have elapsed since patients had anticancer immunotherapy or drug treatment
    3. Less than 4 weeks since cryotherapy, radiofrequency ablation, anhydrous alcohol therapy, or photodynamic therapy, including TACE and TARE
  5. A history of the following cardiovascular diseases (please, consult the Sponsor Medical Monitor for a case by case evaluation):

    1. Congestive heart failure (CHF) that corresponds to Class II or a higher class under (NYHA) classification, or less than 50% of (LVEF)
    2. Uncontrolled hypertension (SBP/DBP >140/90 mmHg) (e.g., patient with SBP/DBP >140/90 mmHg despite the best care including optimizing the anti-hypertensive medication regimen)
    3. Patients with any history of hypertensive crisis or pre-existing hypertensive encephalopathy
    4. Pulmonary hypertension
    5. Myocardial infarction
    6. Uncontrolled arrhythmia
    7. Unstable angina
    8. Patients with any significant vascular diseases (e.g., aortic aneurysm requiring surgery or recent peripheral artery thrombosis) within 6 months prior to the initial treatment of the investigational product
  6. History of reactions to any components of the investigational product or other drugs of the same class (humanized/human monoclonal antibody drugs) or paclitaxel
  7. Patients with to paclitaxel therapy
  8. Patients with persistent, toxicities (excluding hair loss) from previous anticancer treatment that corresponds to Grade 2 or a higher grade under v5.0
  9. Symptomatic or uncontrolled central nervous system (CNS) (However, patients with asymptomatic that have been treated with either surgery or radiation can participate provided that systemic treatment was discontinued at least 4 weeks prior to screening and that the patient is radiologically and neurologically stable or improving)
  10. A history of the following hemorrhage-related or gastroenterological disease:

    1. Active hemorrhage, hemorrhagic diathesis, coagulopathy or tumor in great arteries
    2. History of clinically significant gastroenterological disease, such as peptic ulcer, GI bleeding, GI or non-GI fistula, perforation, abdominal abscess, clinical symptoms, and signs of GI obstruction, need for parenteral hydration or nutrition, or inflammatory bowel disease (IBD)
  11. Current or recent (within 10 days prior to study treatment) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose will be excluded.

    a. Prophylactic (i.e., for the patency of venous access devices) use of low molecular weight heparin (i.e., enoxaparin 40 mg/day) is allowed if patient has \< 2 or aPTT \</=2x within 14 days of study treatment

  12. Patients with current or recent (within 10 days of study treatment) use of aspirin (>81 mg/day), or other nonsteroidal anti-inflammatory drugs (NSAIDs), or other antiplatelets (i.e., dipyramidole, ticlopidine, clopidogrel, and cilostazol) will be excluded.
  13. Severe infection requiring ongoing systemic antibiotics, antivirus drugs, etc., or other uncontrolled acute active infectious diseases
  14. Patients with evidence of active virus (HBV) or virus (HCV) infection. Patients with positive HBsAg and/or detectable HBV DNA are eligible only if adequately controlled on antiviral therapy according to institutional standards and liver function eligibility criteria are also met. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll.
  15. Patients with other severe diseases or uncontrolled illnesses that warrant the exclusion from the study (permitted only if medically controlled) including but not limited to:

    1. Pre-existing hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 28 days prior to screening
    2. Major, unhealed injury, active ulcer, or untreated fracture
    3. Pre-existing conditions of cerebrovascular incident (ischemic or hemorrhagic stroke), or subarachnoid hemorrhage within 6 months prior to screening.
    4. Moderate to severe ascites and/or pleural effusion. However, enrollment is permitted for patients with ascitic fluid as long as paracentesis is not required to improve the condition.
    5. Interstitial lung disease or pulmonary fibrosis
  16. Patients expected to require anticancer treatment other than the investigational product during the clinical study
  17. Pregnant or lactating patients, or patients planning to become pregnant during the clinical study
  18. A history of primary other than BTC will be excluded, except for malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate >90%). Prior malignancy history will be evaluated on a case-by-case basis by the Sponsor Medical Monitor.
  19. Clinically significant abnormal findings or history determined as clinically significant by the Investigator
  20. (Fridericia's formula) (QTcF) interval > 450msec at the time of screening
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    CTX-009 plus Paclitaxel

    Drug: CTX-009 · Drug: Paclitaxel

  • Active comparator
    Paclitaxel

    Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1.

    Drug: Paclitaxel

Interventions

07

What researchers measure

Primary outcomes

  1. Best Overall Response

    Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.

    Time frame: From randomization to treatment discontinuation for any reason, average 6 months

Secondary outcomes

  1. Progression Free Survival

    Time from randomization until the date of objective PD or the date of death (by any cause in the absence of disease progression). Progression of diseases is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From randomization to first documented objective PD or death if PD does not occur, average 6 months

  2. Duration of Response

    Time from the CT or MRI that first confirmed complete (CR) or partial response PR) to the CT or MRI that first confirmed progression of disease progression (PD). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; PD = 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

    Time frame: From first confirmed CR or PR to confirmed PD, average 6 months

  3. Overall Survival

    Time from randomization until the date of death by any cause. Patients who are still alive at the time of the analysis, or who have become lost to follow-up or withdrawn consent will be censored at their last date known to be alive

    Time frame: From randomization to death from any cause, average 12 months

  4. Disease Control Rate

    Percentage of all treated patients whose best overall response was complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

    Time frame: From randomization to treatment discontinuation for any reason, average 6 months

  5. Incidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities

    TEAE is defined by occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-009 or paclitaxel through 30 days after the last dose of CTX-009 or paclitaxel. Change in clinical abnormalities is defined as an increase in abnormality grade in a laboratory result, vital sign, or ECG parameter from predose result to worst postdose result (graded according to the Common Terminology Criteria for Adverse Events v5.0 for all analytes except for brain natriuretic peptide and troponin subtypes, which are interpreted in reference to the laboratory reference range for each), a post-baseline potentially clinically significant vital sign abnormality, or a post-baseline potentially clinically significant ECG abnormality.

    Time frame: From the first dose of either study drug to 30 days after the last dose of study treatment, average 7 months

  6. Efficacy of CTX-009 in combination with paclitaxel in patients who crossed over from the paclitaxel only arm

    Evaluation of ORR, DCR and progression free survival 2 (PFS2) in the crossover set (COS). PFS2 is defined as the time from the first dose of CTX-009 following crossover to the subsequent radiographic progression confirmed by the ICR or death, whichever occurs first

    Time frame: From the first dose of CTX-009 following crossover to the subsequent radiographic progression confirmed by the ICR or death, whichever occurs first

  7. Quality of Life (QoL)

    Changes in QoL scores, as measured using the EORTC QLQ-C30 and BIL21, from baseline in patients treated with CTX-009 in combination with paclitaxel vs. paclitaxel alone

    Time frame: From randomization to treatment discontinuation for any reason, average 6 months

08

Study locations

34 sites
09

References and documents

Publications

  • Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC. Future Oncol. 2024;20(30):2241-2248. doi: 10.1080/14796694.2024.2351351. Epub 2024 Jun 4. PubMed 38861293 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Aug 2027, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2022
First posted
Aug 18, 2022
StartActual
Jan 9, 2023
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Memorial Medical Center · Las Cruces, United States
Show 1 removed
  • Memorial Medical Center · Las Cruces, United States
across 2 updates, Nov 6, 2026 – Nov 10, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionBest Overall Response: how it is measured was reworded
Nov 6, 2026
Secondary outcomes
Revised in 2 updates
What changed on Nov 6, 2026
  • Time frameIncidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalitiesFrom randomization to 60 days after the last dose of study treatment, average 7 months → From the first dose of either study drug to 30 days after the last dose of study treatment, average 7 months
  • DescriptionDisease Control Rate: how it is measured was reworded
  • DescriptionDuration of Response: how it is measured was reworded
  • DescriptionIncidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities: how it is measured was reworded
  • DescriptionProgression Free Survival: how it is measured was reworded
What changed on Nov 10, 2026
  • AddedEfficacy of CTX-009 in combination with paclitaxel in patients who crossed over from the paclitaxel only armTime frame: From the first dose of CTX-009 following crossover to the subsequent radiographic progression confirmed by the ICR or death, whichever occurs first
  • AddedQuality of Life (QoL)Time frame: From randomization to treatment discontinuation for any reason, average 6 months
across 2 updates, Nov 6, 2026 – Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    1 site added
    Show site
    • Memorial Medical Center · Las Cruces, United States
    Secondary outcomes 2 added
    What changed in the outcomes
    • AddedEfficacy of CTX-009 in combination with paclitaxel in patients who crossed over from the paclitaxel only armTime frame: From the first dose of CTX-009 following crossover to the subsequent radiographic progression confirmed by the ICR or death, whichever occurs first
    • AddedQuality of Life (QoL)Time frame: From randomization to treatment discontinuation for any reason, average 6 months
  2. Nov 6, 2026
    1 site removed
    Show 1 removed
    • Memorial Medical Center · Las Cruces, United States
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionBest Overall Response: how it is measured was reworded
    Secondary outcomes 1 time frame changed, 4 description edited
    What changed in the outcomes
    • Time frameIncidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalitiesFrom randomization to 60 days after the last dose of study treatment, average 7 months → From the first dose of either study drug to 30 days after the last dose of study treatment, average 7 months
    • DescriptionDisease Control Rate: how it is measured was reworded
    • DescriptionDuration of Response: how it is measured was reworded
    • DescriptionIncidence of Treatment Emergent Adverse Events (TEAEs) and changes in clinical abnormalities: how it is measured was reworded
    • DescriptionProgression Free Survival: how it is measured was reworded

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05506943
Lead sponsor
Compass Therapeutics
Responsible party
Sponsor
First posted
Aug 18, 2022
Start date
Jan 9, 2023
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Cynthia Sirard, MD
study director · Compass Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovecimig

Start the discussion